Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome episode artwork

EPISODE · Oct 9, 2025 · 3 MIN

Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome

from PCR Perspectives

In this #europcr 2025 interview, Davide Capodanno and Woong Chol Kang explore the latest insights from the 4D-ACS trial and what it could mean for antithrombotic therapy in patients with acute coronary syndrome. They discuss who was included in the trial and walk through the two de-escalation strategies that were tested: reducing the number of the drugs, from dual antiplatelet therapy to single antiplatelet therapy, and lowering the prasugrel dose from 10 mg to 5 mg. Finally, they highlight the key findings that could help refine clinical practice. Listen now to get up to speed in just a few minutes. Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published Oct 9, 2025

Embed this episode

Ready to play

Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome

0:00 3:51

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of PCR Perspectives?

This episode is 3 minutes long.

When was this PCR Perspectives episode published?

This episode was published on October 9, 2025.

Can I download this PCR Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!